Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. more
Time Frame | HRMY | Sector | S&P500 |
---|---|---|---|
1-Week Return | 5.84% | -2.12% | -3% |
1-Month Return | 4.54% | -3.42% | -0.73% |
3-Month Return | -12.75% | -11.13% | 2.87% |
6-Month Return | 18.99% | -5.74% | 7.17% |
1-Year Return | 6.99% | 3.97% | 25.31% |
3-Year Return | -16.59% | 1.05% | 28.38% |
5-Year Return | -7.38% | 34.37% | 81.89% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 6.00M | 159.74M | 305.44M | 437.86M | 582.02M | [{"date":"2019-12-31","value":1.03,"profit":true},{"date":"2020-12-31","value":27.45,"profit":true},{"date":"2021-12-31","value":52.48,"profit":true},{"date":"2022-12-31","value":75.23,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 1.58M | 27.74M | 55.52M | 83.48M | 121.24M | [{"date":"2019-12-31","value":1.3,"profit":true},{"date":"2020-12-31","value":22.88,"profit":true},{"date":"2021-12-31","value":45.79,"profit":true},{"date":"2022-12-31","value":68.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 4.42M | 132.00M | 249.92M | 354.37M | 460.79M | [{"date":"2019-12-31","value":0.96,"profit":true},{"date":"2020-12-31","value":28.65,"profit":true},{"date":"2021-12-31","value":54.24,"profit":true},{"date":"2022-12-31","value":76.91,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 73.69% | 82.64% | 81.82% | 80.93% | 79.17% | [{"date":"2019-12-31","value":89.18,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.02,"profit":true},{"date":"2022-12-31","value":97.94,"profit":true},{"date":"2023-12-31","value":95.81,"profit":true}] |
Operating Expenses | 150.32M | 115.02M | 162.39M | 234.19M | 268.76M | [{"date":"2019-12-31","value":55.93,"profit":true},{"date":"2020-12-31","value":42.8,"profit":true},{"date":"2021-12-31","value":60.42,"profit":true},{"date":"2022-12-31","value":87.14,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (145.90M) | 3.68M | 68.70M | 120.19M | 192.03M | [{"date":"2019-12-31","value":-75.98,"profit":false},{"date":"2020-12-31","value":1.92,"profit":true},{"date":"2021-12-31","value":35.78,"profit":true},{"date":"2022-12-31","value":62.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | (12.15M) | (82.15M) | (74.07M) | (31.17M) | (30.54M) | [{"date":"2019-12-31","value":-1214600000,"profit":false},{"date":"2020-12-31","value":-8215000000,"profit":false},{"date":"2021-12-31","value":-7407000000,"profit":false},{"date":"2022-12-31","value":-3116900000,"profit":false},{"date":"2023-12-31","value":-3054400000,"profit":false}] |
Pre-Tax Income | (151.98M) | (36.94M) | 37.43M | 104.69M | 173.40M | [{"date":"2019-12-31","value":-87.65,"profit":false},{"date":"2020-12-31","value":-21.31,"profit":false},{"date":"2021-12-31","value":21.59,"profit":true},{"date":"2022-12-31","value":60.37,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | 6.07M | 14.91M | 2.83M | (76.78M) | 44.54M | [{"date":"2019-12-31","value":13.63,"profit":true},{"date":"2020-12-31","value":33.48,"profit":true},{"date":"2021-12-31","value":6.36,"profit":true},{"date":"2022-12-31","value":-172.38,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (158.05M) | (51.86M) | 34.60M | 181.47M | 128.85M | [{"date":"2019-12-31","value":-87.1,"profit":false},{"date":"2020-12-31","value":-28.58,"profit":false},{"date":"2021-12-31","value":19.07,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":71.01,"profit":true}] |
Income From Continuous Operations | (151.98M) | (36.94M) | 34.60M | 181.47M | 150.75M | [{"date":"2019-12-31","value":-83.75,"profit":false},{"date":"2020-12-31","value":-20.36,"profit":false},{"date":"2021-12-31","value":19.07,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.08,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (158.05M) | (51.86M) | 34.60M | 181.47M | 128.85M | [{"date":"2019-12-31","value":-87.1,"profit":false},{"date":"2020-12-31","value":-28.58,"profit":false},{"date":"2021-12-31","value":19.07,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":71.01,"profit":true}] |
EPS (Diluted) | - | (2.82) | 0.83 | 3.13 | 2.42 | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-90.1,"profit":false},{"date":"2021-12-31","value":26.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":77.32,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
HRMY | |
---|---|
Cash Ratio | 2.55 |
Current Ratio | 3.24 |
Quick Ratio | 3.20 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
HRMY | |
---|---|
ROA (LTM) | 12.85% |
ROE (LTM) | 22.75% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
HRMY | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.36 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.64 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
HRMY | |
---|---|
Trailing PE | 16.06 |
Forward PE | 8.58 |
P/S (TTM) | 2.83 |
P/B | 3.24 |
Price/FCF | 27 |
EV/R | 2.50 |
EV/Ebitda | 7.83 |
Harmony Biosciences Holdings (HRMY) share price today is $34.28
Yes, Indians can buy shares of Harmony Biosciences Holdings (HRMY) on Vested. To buy Harmony Biosciences Holdings from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HRMY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Harmony Biosciences Holdings (HRMY) via the Vested app. You can start investing in Harmony Biosciences Holdings (HRMY) with a minimum investment of $1.
You can invest in shares of Harmony Biosciences Holdings (HRMY) via Vested in three simple steps:
The 52-week high price of Harmony Biosciences Holdings (HRMY) is $41.61. The 52-week low price of Harmony Biosciences Holdings (HRMY) is $28.14.
The price-to-earnings (P/E) ratio of Harmony Biosciences Holdings (HRMY) is 16.0616
The price-to-book (P/B) ratio of Harmony Biosciences Holdings (HRMY) is 3.24
The dividend yield of Harmony Biosciences Holdings (HRMY) is 0.00%
The market capitalization of Harmony Biosciences Holdings (HRMY) is $1.93B
The stock symbol (or ticker) of Harmony Biosciences Holdings is HRMY